Last reviewed · How we verify
two doses enterovirus 71 vaccine
This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against enterovirus 71, preventing infection and disease.
This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against enterovirus 71, preventing infection and disease. Used for Prevention of enterovirus 71 infection and associated hand, foot, and mouth disease, Prevention of enterovirus 71-associated neurological complications in infants and young children.
At a glance
| Generic name | two doses enterovirus 71 vaccine |
|---|---|
| Sponsor | Beijing Chaoyang District Centre for Disease Control and Prevention |
| Drug class | inactivated viral vaccine |
| Target | Enterovirus 71 viral antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | FDA-approved |
Mechanism of action
Enterovirus 71 vaccine contains inactivated virus particles that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes viral antigens and develops protective immunity, reducing the risk of infection and severe disease manifestations such as hand, foot, and mouth disease and neurological complications.
Approved indications
- Prevention of enterovirus 71 infection and associated hand, foot, and mouth disease
- Prevention of enterovirus 71-associated neurological complications in infants and young children
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Irritability or fussiness
Key clinical trials
- Study on the Persistence of Immunity Following EV71 Vaccination
- Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell) (PHASE3)
- A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children (PHASE3)
- Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine (PHASE4)
- Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months (PHASE2)
- A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
- Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months (PHASE3)
- Immunogenicity and Safety of Two Different Commercial EV71 Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: